Research programme: progressive multifocal leukoencephalopathy therapies - Alnylam Pharmaceuticals/Biogen

Drug Profile

Research programme: progressive multifocal leukoencephalopathy therapies - Alnylam Pharmaceuticals/Biogen

Alternative Names: JC virus RNAi therapeutics - Alnylam Pharmaceuticals/Biogen; PML RNAi therapeutics - Alnylam Pharmaceuticals/Biogen

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Biogen Idec
  • Developer Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Progressive multifocal leukoencephalopathy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Progressive multifocal leukoencephalopathy in USA
  • 01 Apr 2008 Pharmacodynamics data from a preclinical study in Progressive multifocal leukoencephalopathy released by Alnylam
  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in progressive multifocal leukencephalopathy presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top